Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Other Non-Current Liabilities (2023 - 2025)

Guardian Pharmacy Services (GRDN) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 18.24% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 18.24% year-over-year, with the annual reading at $4.0 million for FY2025, 18.24% up from the prior year.
  • Other Non-Current Liabilities hit $4.0 million in Q4 2025 for Guardian Pharmacy Services, down from $5.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $31.5 million in Q4 2023 to a low of $3.3 million in Q3 2024.
  • Historically, Other Non-Current Liabilities has averaged $8.2 million across 3 years, with a median of $4.0 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 89.15% in 2024 and later surged 57.97% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $31.5 million in 2023, then plummeted by 89.15% to $3.4 million in 2024, then grew by 18.24% to $4.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for GRDN at $4.0 million in Q4 2025, $5.2 million in Q3 2025, and $6.2 million in Q2 2025.